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Controversy over how to fund and regulate
stem cell research continues in the US and is
unlikely to be resolved anytime soon. The
National Institutes of Health (NIH) has an-
nounced that it is prepared to fund stem cell
research under yet-to-be-specified guidelines. The National
Bioethics Advisory Commission (NBAC) issued a report on
stem cells in mid-September, recommending that Congress
change the law to permit the derivation and use of stem cells
from embryos no longer needed for reproduction purposes
that are stored at in vitro fertilization (IVF) clinics. The NBAC
also recommended that the Department of Health and Human
Services (DHHS) establish a new National Stem Cell Oversight
and Review Panel to ensure that all federally funded stem cell
research meets ethical standards. So far, the outgoing NIH di-
rector Harold Varmus has indicated that NIH will stick with its
previous position and develop its own research guidelines.
President Clinton seems to be in accord with Varmus, as is the
American Association for the Advancement of Science.
American politics surrounding embryo research, and any re-
search relating to abortion, are complex and divisive. We be-
lieve it is time for a congressional debate on the funding,
ethics and federal oversight of stem cell research. The NBAC
report provides a useful opportunity for Congress to take this
research seriously.
Political attention in the United States is focusing on stem
cell research mainly because of two scientific reports1,2 and a
November 1998 press release, all promising the potential of
wide therapeutic applications if further research is actively
pursued. Although ethical debate on stem cell research is in
its infancy and should continue, federal law governing both
stem cell research and federal funding and oversight of it
needs to be clarified now. This is because the stakes are very
high—stem cell research holds the promise of producing spe-
cialized, replacement cells to treat a variety of diseases and
conditions, including parkinsonism, spinal cord injury,
stroke, burns, heart disease, diabetes, osteoarthritis and
rheumatoid arthritis.
There are a variety of stem cells. Of most direct concern now
are totipotent stem cells (capable of giving rise to an entire or-
ganism) and pluripotent stem cells (capable of giving rise to
different kinds of cells, but not an entire organism).
Totipotent stem cells exist in the very early embryo; pluripo-
tent cells can be isolated from blastocyts, placental blood,
bone marrow and fetal tissue. The reason stem cell research is
politically controversial is the source of the stem cells.
Whereas there is, for example, no controversy about research
that uses stem cells derived from placental blood or bone mar-
row, the controversy relates exclusively to stem cells obtained
either from human embryos or the reproductive tissues of
aborted fetuses. Stem cell research is yet another chapter in
America’s long-running battle over the ethics of elective abor-
tion.
There are many different ways to obtain
human embryos to serve as the source for
pluripotent and totipotent cells. University
of Wisconsin scientists derived the stem cells
they immortalized from human embryos that were left over,
‘spare’ or ‘orphan’ embryos1. These are human embryos that
had been created in an IVF clinic for use in reproduction that
were later donated by couples who no longer needed them or
no longer wished to use them to have a child. Johns Hopkins
University researchers derived their stem cells from primordial
germ cells excised from the gonadal ridges and mesenteries of
5- to 9-week aborted fetuses2. And University of Massachusetts
researchers and Advanced Cell Technology claim to have cre-
ated an embryo from an enucleated cow egg and human nu-
clear DNA that gave rise to stem cells. (The last claim has not
been published in the scientific literature or otherwise sub-
stantiated.) Although often discussed in the same ethical
breath, each of these sources of stem cells raises different legal
and ethical problems.
Stem cells from human fetuses
One of the first actions President Clinton took upon becoming
president in January 1993 was to lift the DHHS’s moratorium
on federal funding for research involving the transplantation
of fetal tissue from induced abortions. He did so on the
grounds that the moratorium “...has significantly hampered
the development of possible treatments for individuals af-
flicted with serious diseases and disorders, such as Parkinson’s
disease, Alzheimer’s disease, diabetes, and leukemia3.” Current
federal law continues to permit federal funding of research in-
volving human fetal tissues, including stem cells, derived from
dead fetuses, with three basic restrictions: There is a criminal
prohibition against the sale of human fetal tissue for a price ex-
ceeding expenses of procuring and delivering it; informed con-
sent is required if fetal tissue is to be used for therapeutic
transplants; and finally, a prohibition exists on donating fetal
tissue to a designated donee4.
Thus, under existing federal law, the federal government
may fund research using stem cells derived from elective abor-
tions of the type done by the Johns Hopkins researchers, at
least if the research is done in states that do not prohibit it.
The fight to prohibit the use of fetal tissues for research has
been fought and lost in Congress, with the interests of the mil-
lions of Americans suffering from diseases that could possibly
be ameliorated by such research taking precedence over ethi-
cal concerns about complicity in the practice of abortion itself
or the moral status of the fetus. Arguments that would restrict
such research to spontaneously aborted fetuses have been re-
jected on the basis that there is a biologic reason for such an
abortion, such as infection or a genetic abnormality, both
making the use of such tissue inappropriate3,5.
Tremendous controversy has surrounded efforts to undertake research on totipotent human stem cells. To date public policy in the
United States has attempted to skirt the ethical and social questions raised by this research. Annas et al. argue that research using
human embryos as a source of totipotent stem cells can secure broad public support if there is an open and public discussion about
the ethical justification for undertaking such research and the assurance of adequate federal regulation and oversight.
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Embryonic stem cells
The creation of embryos for the purpose of research has been
ethically and politically contentious. Current law, for example,
prohibits federal funding for the creation of a human embryo
or embryos for research purposes; or for research in which a
human embryo or embryos are destroyed, discarded, or know-
ingly subjected to risk of injury or death greater than that al-
lowed for research on fetuses in utero under 45 Code of Federal
Regulations 46.208(a)(2) and section 498(b) of the Public
Health Act6.
The term “human embryo or embryo” is defined as “any or-
ganism, not protected as a human subject…that is derived by
fertilization, parthenogenesis, cloning, or any other means from
one or more human gametes or human diploid cells6.” Under
this law, the NIH may not fund any research in which human
embryos are created for research purposes, nor research in
which any human embryos are destroyed. Thus, under existing
law, the NIH could not fund the University of Wisconsin re-
search.
We have previously suggested that the use of ‘spare’ or ‘sur-
plus’ embryos from IVF clinics is ethically appropriate, mainly
because they were created for procreative purposes that will no
longer be fulfilled7. The creation of embryos for reproductive
purposes with the consent of those providing their gametes is
not ethically suspect. If it is granted that the moral standing of a
frozen embryos derives more from its role in the context of
human reproduction than in its physical properties7, then when
a couple no longer wants them for procreation, they should be
able to donate them for research. The choice of donating spare
embryos for use in important medical research that cannot be
done by other means is ethically superior to either destroying
them or keeping them perpetually cryopreserved7.
The NIH, at least temporarily, has chosen not to ask Congress
to reconsider or rewrite this ban. Instead, the NIH, on advice of
counsel, has concluded that as pluripotent stem cells are not
themselves “organisms” under the definition, NIH may fund re-
search on such stem cells4. We agree with this as a narrow legal
conclusion; but it raises the ethical question of where the em-
bryos are obtained and the possibility of complicity in embryo
destruction. In this regard, the NBAC has rightly rejected the
NIH’s position, noting “There is no compelling ethical justifica-
tion for distinguishing between the derivation and use of
human stem cells8.”
But it is important to go further. Failure to explicitly address
the ethics of using spare embryos as a source of stem cells not
only invites continued political and ethical controversy and
public disquiet but cedes the moral case to opponents of their
use. Although the destruction of a human embryo is lamenta-
ble, there is a considerable moral difference between creating
and destroying embryos solely to obtain stem cells and destroy-
ing unwanted human embryos that will never be used for repro-
ductive purposes, to achieve benefit for those with serious
diseases and disorders. The former involves the creation solely
for the purpose of destruction whereas the latter involves sal-
vaging something of value from a situation from which nothing
else can be gained.
Embryos created by nuclear transfer
The use of human embryos created by transferring the nucleus
of a somatic cell into an enucleated egg to produce stem cells
cannot be federally funded if the research results in the destruc-
tion of the embryo. About a dozen states also regulate embryo
research to varying degrees9. We do not know what the
Massachusetts researchers (from Advanced Cell Technology) ac-
tually did, but their 12 November 1998 press release states that
the researchers “successfully developed a method for producing
primitive human embryonic stem cells through nuclear transfer
techniques (cloning).” Later, authors from Advanced Cell
Technology went on to state “Several years ago, we transferred
nuclei from human somatic cells (18 lymphocytes and 34 oral
mucosal epithelial cells) into enucleated bovine oocytes to form
a preimplantation embryo… of the 56 nuclear transfer units
produced…only 1 reached the 16- to 400-cell stage10.” Their
claim, in other words, is that they created a human embryo
using human DNA and the enucleated egg of a cow. Their press
release promised, “We will not use this technology to clone
human beings.”
Many are troubled by the prospect of using human DNA to
cross species boundaries. Mostly, concerns relate to attempts to
create a whole organism, a human–animal hybrid. But there is
also ample concern for safety even if the only goal is to create
cells or tissues for human use. The long-term effect of using
human nuclear chromosomes with shortened telomeres or cy-
toplasm containing animal mitochondrial DNA on the function
and survival of newly created tissues remains uncertain. Safety
concerns about this sort of genetic engineering must be taken
very seriously.
It is especially disturbing that the only example of cross-
species nuclear transfer has only been reported by press release.
The protocol (if one existed) was not reviewed by the University
of Massachusetts’ local Institutional Review Board (IRB), even
though state law which requires IRB review of this type of re-
search. It is a crime in Massachusetts “...to use any live human
fetus [which the statute defines as including “an embryo”] …for
scientific, laboratory, research or other kind of experimenta-
tion11.” Although the statute was not written with this type of
research in mind, it applies to the creation of human embryos
for research, and provides mechanisms such as prior review by
IRBs, by which protocols that might run afoul of the law can be
reviewed before they are initiated. The researchers, who were
veterinarians and not physicians, may not have been aware of
the ethical or legal dimensions of their research.
Federal policy and stem cell research
Advanced Cell Technology said it put out its press release to en-
courage debate about the ethics of what they had done. But
this is not a reasonable course for provoking ethical debate.
Ethics must be discussed before proceeding, not after the re-
search is a fait accompli. Given the safety unknowns of mixing
human nuclear DNA with bovine mitochrondrial DNA, there is
a powerful moral case against using this source of stem cells in
human beings.
All research on totipotent and pluripotent stem cells in the
US is now being done in the private sector without federal reg-
ulatory or ethical oversight. All three of the studies mentioned
here were financed by private, for-profit biotechnology compa-
nies. Geron Corporation, which funded both of the two pub-
lished studies, decided to set up its own ethics advisory board.
The board’s first statement, however, was not drafted until the
research was complete and both papers had been accepted for
publication12. This seems more like ‘ethical cover’ rather than
ethics that can be taken seriously, especially as the board
rewrote their statement after the publication of the study’s 
results.
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The Geron ethics board repeated a phrase that often appears
in discussions of the ethics of research involving the human
embryo—that the embryo must be “treated with respect.”
Despite its prominence in discussions of embryo and stem cell
research, the phrase “treated with respect” borders on the trite.
It is not clear what respect for an embryo means. Geron’s only
real measure of respect is that the embryo be used “...with care
only in research that incorporates substantive values such as re-
duction of human suffering12.” The idea of respect is particularly
jarring in the context of research that of necessity results in the
destruction of the embryo. It is time to abandon this language
in favor of an examination of whether or not the destruction of
certain types of embryos can be justified in terms of the benefits
to be produced through their use in research.
The Geron Ethics Board appropriately discussed informed
consent, but remarkably (for an ethics board) approved a form
provided to IVF patients to donate their embryos that states:
“You will not benefit financially [from the research]…The cells
derived in this study may be shared with Geron Corporation, lo-
cated in Menlo Park, CA, as part of the study. Geron
Corporation may benefit financially from the development and
clinical use of the cells derived in this study12.” The board de-
scribes this statement as “explicit” and “exemplary”, although it
is almost certain that no IVF patient would know anything
about Geron Corporation (other than where its corporate head-
quarters is located) or whether they want to make a personal do-
nation to their for-profit research efforts. It is, in short, an
inadequate level of disclosure.
Most saliently, Geron’s ethics board states as a final ethical
principle that “all such research must be done in a context of
concern for global justice.” The ethics board seems to recognize
what few, if any, Geron stockholders would concede: If only the
rich are likely to benefit from stem cell research, it should not be
pursued at all as a matter of social justice. This principle follows
from ideas of respect for embryonic and fetal tissue that permit
its instrumental use only to “alleviate human suffering and to
promote the health and well-being of human populations,” but
obviously begs the question of whether for-profit corporations
can ever have this as a realistic goal or how the company could
be forced to adhere to this principle. As stated in the context of a
policy that seems to have been created to provide an ethical ra-
tionalization rather than as an ethical guidance for research, it is
not likely that it can or will be taken seriously.
Stem cell research ethics and the federal government
A decision by Congress not to fund an area of research at all, like
research involving human embryos, simply leaves the private
sector to make up its own rules (at least in the absence of a spe-
cific state law). As the drug market is driven by the goal of profit
maximization, there is no obvious way for ethical or social jus-
tice considerations to become a part of corporate policy. If the
federal government wants to actually influence how research is
done on human embryos and fetal tissue, it must set forth clear
and unequivocal rules that cover not just the research it funds,
but all research, including privately financed research.
Debate at the federal level on embryo research has been pur-
sued for more than 20 years with little to show for it other than
driving most research into the hands of private corporations.
This is unsatisfactory public policy for an area of research that
has profound social policy implications. The oversight and reg-
ulation of stem cell research is too important to be left to private
corporations. Rules for basic medical research involving fetal tis-
sues and human embryos can and should be publicly developed
and enforced at the federal level.
We think that research using human embryos can secure US
public support if that support is accompanied by much more ex-
plicit and open federal regulation and oversight. A federal over-
sight panel, independent of the NIH and DHHS, should be
created with authority to promulgate all regulations for research
involving the use of human embryos, the authority to review
and approve (or disapprove) all research projects in the US that
use human embryos, as well as all research projects using stem
cells and other cell lines derived from human embryos or
aborted fetuses7. This oversight panel, which will have to be au-
thorized by Congress, should be composed mainly of members
of the public, but should also include scientific, medical, legal
and ethical experts, as well as experts on religious doctrine. The
panel must have sufficient funding and staff to undertake its du-
ties. To have impact outside the US an international treaty is re-
quired. This would be a prudent course to follow.
All US research in any way related to abortion, including re-
search on human embryos, has been held hostage to the politics
of the American abortion debate3,7, a debate that has not proven
susceptible to political resolution. This does not mean that stem
cell research must meet the same fate. The promise of stem cell
research for millions of patients may afford an outcome in
which the ethical debate can be resolved democratically in
Congress. This opportunity to move from ethical gridlock to re-
sponsible ethical oversight of such research should not be
missed. Our society can and should decide, through its
Congress, what embryos should be used as sources of stem cells
for research, what oversight must be in place in both the public
and private sectors, and what limits should be placed on cross-
species research.
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